SomaLogic Inc has entered into an agreement with the National Cancer Institute (NCI). Under the agreement, SomaLogic will develop aptamers for NCI-supplied proteins. NCI investigators will be able to use the aptamers in specific research applications, while SomaLogic will retain the right to use the aptamers on its proteomic arrays.

Developing antibodies for novel targets can be challenging and time-consuming. Aptamers represent a practical alternative and are intended to complement existing research tools.

"This agreement gives the NCI access to our proprietary aptamer technology," stated Dr. Larry Gold, SomaLogic's Chief Scientific Officer. "We look forward to working together to develop aptamers to novel targets."